These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 1979818)

  • 1. Hypertension, coronary risk and alpha-blockade.
    J Hum Hypertens; 1990 Oct; 4 Suppl 3():1-65. PubMed ID: 1979818
    [No Abstract]   [Full Text] [Related]  

  • 2. [Reduction of coronary risk factors with selective alpha-blockers. International Doxazosin Symposium. Frankfurt/Main, 7 June 1986].
    Fortschr Med Suppl; 1986; 8():1-19. PubMed ID: 2876941
    [No Abstract]   [Full Text] [Related]  

  • 3. The value of alpha-blockers in the management of hypertension: a practical view.
    McInnes GT
    J Hum Hypertens; 1991 Aug; 5(4):313-6. PubMed ID: 1683406
    [No Abstract]   [Full Text] [Related]  

  • 4. Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
    Pool JL; Lenz ML; Taylor AA
    J Hum Hypertens; 1990 Oct; 4 Suppl 3():23-33. PubMed ID: 1979819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical settings for selective alpha-adrenergic receptor inhibition: rationale and management strategies. Proceedings of a symposium. Naples, Florida, October 13 to 16, 1988.
    Am J Med; 1989 Aug; 87(2A):1S-66S. PubMed ID: 2569821
    [No Abstract]   [Full Text] [Related]  

  • 6. Alpha 1-blockade in the management of hypertension.
    Horky K
    J Clin Pharmacol; 1993 Sep; 33(9):874-8. PubMed ID: 7901241
    [No Abstract]   [Full Text] [Related]  

  • 7. Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
    Westheim A; Daae LN; Kierulf P; Brusletto B; Holme I; Syvertsen JO
    J Hypertens Suppl; 1990 Sep; 8(5):S41-6. PubMed ID: 1981076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A symposium: Doxazosin: coronary artery disease risk factor management. June 7, 1986, Frankfurt, Germany.
    Am J Cardiol; 1987 May; 59(14):1G-104G. PubMed ID: 2954453
    [No Abstract]   [Full Text] [Related]  

  • 9. Doxazosin, a new alpha-1-antagonist drug, controls hypertension without causing airways obstruction in asthma and COPD.
    Biernacki W; Flenley DC
    J Hum Hypertens; 1989 Dec; 3(6):419-25. PubMed ID: 2575174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of alpha 1-blockers in combination therapy for hypertension.
    Zusman RM
    Int J Clin Pract; 2000; 54(1):36-40. PubMed ID: 10750258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents.
    Louis WJ; McNeil JJ; Anavekar SN; Conway EL; Workman B; Howes LG; Drummer OH; Jarrott B
    J Cardiovasc Pharmacol; 1987; 10 Suppl 12():S100-3. PubMed ID: 2455158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of doxazosin and atenolol on serum lipids and blood pressure in hypertensive smokers.
    Talseth T; Westlie L; Daae LN
    J Hypertens Suppl; 1990 Sep; 8(5):S47-51. PubMed ID: 1981077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terazosin for hypertension.
    Med Lett Drugs Ther; 1987 Dec; 29(755):112-3. PubMed ID: 2891021
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of coronary heart disease risk factors in hypertensive patients: clinical experience with doxazosin. A symposium. London, England, January 26, 1990. Proceedings.
    Am Heart J; 1991 Jan; 121(1 Pt 2):245-406. PubMed ID: 1670742
    [No Abstract]   [Full Text] [Related]  

  • 15. Alpha-blocker therapy of hypertension. An unfulfilled promise.
    Khoury AF; Kaplan NM
    JAMA; 1991 Jul; 266(3):394-8. PubMed ID: 1676077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects.
    Feher MD; Henderson AD; Wadsworth J; Poulter C; Gelding S; Richmond W; Sever PS; Elkeles RS
    J Hum Hypertens; 1990 Oct; 4(5):571-7. PubMed ID: 1980930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Terazosin in mild hypertension: experience in open trials.
    Rosenthal J
    Br J Clin Pract Suppl; 1987 Dec; 54():32-44. PubMed ID: 2905160
    [No Abstract]   [Full Text] [Related]  

  • 18. Implications of doxazosin therapy on risk of coronary heart disease.
    Hansson L
    Am Heart J; 1988 Dec; 116(6 Pt 2):1832-7. PubMed ID: 2904759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First European review of terazosin. Proceedings of a symposium. Reykjavik, Iceland, 29th-31st May 1987.
    Br J Clin Pract Suppl; 1987 Dec; 54():1-69. PubMed ID: 2905157
    [No Abstract]   [Full Text] [Related]  

  • 20. Alpha 1-adrenoreceptor blockade in hypertension: pharmacological and clinical profile of doxazosin. Proceedings of an international symposium. Venice, Italy, 14 June 1985.
    Br J Clin Pharmacol; 1986; 21 Suppl 1():1S-92S. PubMed ID: 2939864
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.